Skip to content
Screener

West Pharmaceutical Services WST Other Non-Current Liabilities

Other Non-Current Liabilities at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$2.46B-17.9%
AptarGroup logo
AptarGroupATR
$37.5M—
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$102.68M+32.0%
AVT
AvantorAVTR
$383M-2.1%
Dow logo
DowDOW
$8.65B+25.8%
DuPont de Nemours, Inc. logo
DuPont de Nemours, Inc.DD
$1.18B-10.8%

Other financials

Income statement

See full
Revenue$872.3M+13.8%
Gross profit$329.2M+20.2%
Operating income$179.1M+16.5%
Net income$154.0M+16.8%
EPS (diluted)$2.15+18.1%

Balance sheet

See full
Cash & equivalents$435.8M-14.5%
Total debt$316.5M+2.7%
Total equity$3.0B+2.1%
Total assets$4.1B+3.1%

Cash flow

See full
Operating cash flow$124.0M-30.0%
CapEx$43.2M-42.6%
Free cash flow$80.8M-20.7%

Valuation

See full
Market cap$24.53B+43.8%
Enterprise value$24.41B+44.8%
P/E43.4×+8.4×
P/S7.4×+1.6×

Profitability

See full
Gross margin36.8%+1.5pp
Operating margin20.5%+0.8pp
Net margin17%+0.5pp
FCF margin13.1%+1.5pp

Returns & leverage

See full
Return on equity19.1%+1.4pp
Debt / equity0.1×0.0×
Current ratio2.8×0.0×

Where this comes from

Reported directly by West Pharmaceutical Services in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.

The source filing: West Pharmaceutical Services’s 10-Q, filed July 23, 2026.

Filed
Jul 23, 2026, 4:15 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000105770-26-000099
(in millions, except per share data)June 30,2026December 31,2025
Pension and other postretirement benefits28.329.0
Operating lease liabilities88.395.6
Deferred compensation benefits13.913.5
Other long-term liabilities89.975.2
Total Liabilities1,086.21,094.0
Commitments and contingencies (Note 16)
Equity:
Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding——

Item 1. FINANCIAL STATEMENTS (UNAUDITED)

FAQ

What is West Pharmaceutical Services's other non-current liabilities?
West Pharmaceutical Services (WST) reported other non-current liabilities of $89.9M in Q2 2026.
How has West Pharmaceutical Services's other non-current liabilities changed year-over-year?
West Pharmaceutical Services's other non-current liabilities increased by 27.7% year-over-year, from $70.4M to $89.9M.
What is the long-term trend for West Pharmaceutical Services's other non-current liabilities?
Over 5 years (2020 to 2025), West Pharmaceutical Services's other non-current liabilities has grown at a 18.8% compound annual growth rate (CAGR), from $31.8M to $75.2M.
What does other non-current liabilities mean?
Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.

Ask your AI about West Pharmaceutical Services's other non-current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude